glp 1 agonist novo nordisk Details of failed studies cast pall on Nordisk's GLP-1 as Alzheimer's treatment Ozempic's patent problem: how Novo
Description
- **Curb appetite:** Helping individuals feel full, potentially leading to reduced food intake
In a letter, the FDA said it needs more data to fully understand several possible risks tied to the drug, including heart and liver problems.
Thus, pitfalls in the methodology of these studies have led sometimes to misleading results
Two clinical studies show 200%+ GLP-1 increase & up to 25 lbs lost in 12 weeks
PlexusDx routes every Microdose GLP-1 patient to a licensed clinician in all 50 states
